Division of Critical Care, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, USA.
Pediatr Crit Care Med. 2012 Jan;13(1):e33-8. doi: 10.1097/PCC.0b013e31820ac08f.
Pediatric acute liver failure is often accompanied by hepatic encephalopathy, cerebral edema, and raised intracranial pressure. Elevated intracranial pressure can be managed more effectively with intracranial monitoring, but acute-liver-failure-associated coagulopathy is often considered a contraindication for invasive monitoring due to risk for intracranial bleeding. We reviewed our experience with use of early intracranial pressure monitoring in acute liver failure in children listed for liver transplantation.
Retrospective review of all intubated pediatric acute liver failure patients with grade III and grade IV encephalopathy requiring intracranial pressure monitoring and evaluated for potential liver transplant who were identified from an institutional liver transplant patient database from 1999 to 2009.
None.
A total of 14 patients were identified who met the inclusion criteria. Their ages ranged from 7 months to 20 yrs. Diagnoses of acute liver failure were infectious (three), drug-induced (seven), autoimmune hepatitis (two), and indeterminate (two). Grade III and IV encephalopathy was seen in ten (71%) and four (29%) patients, respectively. Computed tomography scans before intracranial pressure monitor placement showed cerebral edema in five (35.7%) patients. Before intracranial pressure monitor placement, fresh frozen plasma, vitamin K, and activated recombinant factor VIIa were given to all 14 patients, with significant improvement in coagulopathy (p < .04). The initial intracranial pressure ranged from 5 to 50 cm H2O; the intracranial pressure was significantly higher in patients with cerebral edema by computed tomography (p < .05). Eleven of 14 (78%) patients received hypertonic saline, and three (22%) received mannitol for elevated intracranial pressure. Eight of 14 (56%) monitored patients were managed to liver transplant, with 100% surviving neurologically intact. Four of 14 (28%) patients had spontaneous recovery without liver transplant. Two of 14 (14%) patients died due to multiple organ failure before transplant. One patient had a small 9-mm intracranial hemorrhage but survived after receiving a liver transplant. No patient developed intracranial infection.
In our series of patients, intracranial pressure monitoring had a low complication rate and was associated with a high survival rate despite severe hepatic encephalopathy and cerebral edema in the setting of pediatric acute liver failure. In our experience, monitoring of intracranial pressure allowed interventions to treat increased intracranial pressure and provided additional information regarding central nervous system injury before liver transplant. Further study is warranted to confirm if monitoring allows more directed intracranial pressure therapy and improves survival in pediatric acute liver failure.
小儿急性肝衰竭常伴有肝性脑病、脑水肿和颅内压升高。颅内压升高可以通过颅内监测更有效地进行管理,但由于颅内出血的风险,急性肝衰竭相关的凝血障碍通常被认为是侵入性监测的禁忌症。我们回顾了我们在小儿急性肝衰竭患者中使用早期颅内压监测的经验,这些患者被列入肝移植名单,且伴有 III 级和 IV 级脑病,需要颅内压监测,并评估了可能的肝移植。
从 1999 年至 2009 年的机构肝移植患者数据库中,回顾性分析了所有需要颅内压监测的气管插管的小儿急性肝衰竭患者,并评估了潜在的肝移植患者,这些患者均伴有 III 级和 IV 级脑病。
无。
共确定了 14 名符合纳入标准的患者。他们的年龄从 7 个月到 20 岁不等。急性肝衰竭的诊断包括感染(3 例)、药物诱导(7 例)、自身免疫性肝炎(2 例)和原因不明(2 例)。10 例(71%)和 4 例(29%)患者分别出现 III 级和 IV 级脑病。颅内压监测前的计算机断层扫描显示 5 例(35.7%)患者有脑水肿。颅内压监测前,所有 14 例患者均给予新鲜冷冻血浆、维生素 K 和重组活化因子 VIIa,凝血障碍明显改善(p<0.04)。初始颅内压范围为 5 至 50cmH2O;颅内压在 CT 显示脑水肿的患者中明显升高(p<0.05)。14 例患者中有 11 例(78%)接受高渗盐水,3 例(22%)接受甘露醇治疗颅内压升高。14 例监测患者中有 8 例(56%)接受肝移植治疗,100%患者神经功能完整存活。14 例患者中有 4 例(28%)无肝移植而自发性恢复。2 例(14%)患者在移植前因多器官衰竭死亡。1 例患者出现 9mm 小量颅内出血,但在接受肝移植后存活。无患者发生颅内感染。
在我们的患者系列中,尽管小儿急性肝衰竭伴有严重的肝性脑病和脑水肿,但颅内压监测的并发症发生率较低,存活率较高。根据我们的经验,监测颅内压可以进行治疗颅内压升高的干预措施,并在肝移植前提供有关中枢神经系统损伤的额外信息。需要进一步研究以确认监测是否可以进行更有针对性的颅内压治疗,并提高小儿急性肝衰竭的生存率。